{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:27:31Z","timestamp":1793298451252,"version":"4.5.0"},"reference-count":13,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180794"],"award-info":[{"award-number":["U10CA180794"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Nivolumab showed durable responses in patients with small cell lung cancer (SCLC). A randomized phase II study investigating nivolumab plus cisplatin\/carboplatin and etoposide (PE) versus PE for patients with untreated extensive\u2010stage (ES) SCLC was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with untreated ES\u2010SCLC, Eastern Cooperative Oncology Group performance status 0\u20101, were randomized 1:1 to nivolumab 360 mg intravenously (IV) plus cisplatin 75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or carboplatin area under the curve 5 on day 1 and etoposide 100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (PE) on days 1\u20133 every 21 days for four cycles followed by nivolumab 240 mg intravenously (arm A) every 2 weeks on a 6\u2010week cycle for up to 2 years or PE alone (Arm B) for 4 cycles followed by observation. The primary endpoint was progression\u2010free survival (PFS). The primary comparison of PFS used a logrank test stratified on the randomization stratification factors with a one\u2010sided type I error rate of 10%. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 160 patients were enrolled; 144 patients were treated and constituted the primary analysis. The median PFS was 5.5 months (95% confidence interval [CI], 4.3\u20135.9 months) on arm A, and 4.9 months (95% CI, 4.5\u20135.7 months) on arm B (hazard ratio, 0.78;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.083). The estimated median OS was 11.2 months (95% CI, 8.8\u201314.2 months) on arm A and 8.1 months (95% CI, 7.2\u20139.6 months) on arm B (hazard ratio, 0.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.059).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of PE and nivolumab improves both PFS and OS for patients with ES\u2010SCLC. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.35938","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:24:02Z","timestamp":1750209842000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive\u2010stage small cell lung cancer (ES\u2010SCLC): ECOG\u2010ACRIN EA5161"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-9063","authenticated-orcid":false,"given":"Ticiana A.","family":"Leal","sequence":"first","affiliation":[{"name":"Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute ECOG\u2010ACRIN Biostatistics Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-6839","authenticated-orcid":false,"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[{"name":"Case Western Reserve University  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Chay","sequence":"additional","affiliation":[{"name":"Messino Cancer Centers  Asheville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Research Consortium of West Michigan NCORP  Grand Rapids Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit R.","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Henry Ford Cancer Institute  Detroit Michigan US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Razaq","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center  Oklahoma City Oklahoma USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish G.","family":"Ajuja","sequence":"additional","affiliation":[{"name":"Aspirus Regional Cancer Center  Wausau Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Illinois Cancer Care\u2010Peoria  Peoria Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"King","sequence":"additional","affiliation":[{"name":"Metro Minnesota Community Oncology Res Consortium  Fridley Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sumey","sequence":"additional","affiliation":[{"name":"Sanford Cancer Center Oncology Clinic  Sioux Falls South Dakota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"American Cancer Society.Cancer Facts and Figures;2024."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01881"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.004"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(19)32222\u20106"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01055"},{"key":"e_1_2_9_12_1","volume-title":"Presented at: WCLC International Congress 2023","author":"Liu S","year":"2023"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30539\u20108"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00793"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:53:17Z","timestamp":1760295197000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,6,15]]}},"alternative-id":["10.1002\/cncr.35938"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35938","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"2024-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35938"}}